[3] CEO Alex Gorsky said that the split was in response to "a significant evolution in these markets, particularly on the consumer side",[3] and would enable faster expansion for both businesses.

[10] The Times also pointed out that, while the consumer health business operates many well-known brands, it was not nearly as lucrative as the pharmaceutical and medical device sectors (taking $15 billion in revenue in 2021 compared to the latter's combined $77 billion), commenting that the popularity of the consumer brands "does not do much to advance Johnson & Johnson's medical businesses, which are far more important to the company's finances".

They said that the name was a combination of "ken", a Scottish English word for 'knowledge', and "vue", a homophone of "view" intended to evoke the concept of 'sight'.

[16][29][7] Consumer brands operated by Kenvue include: A securities class action was initiated in the United States District Court of New Jersey by law firm Kessler Topaz Meltzer & Check, LLP on 9 October 2023.

The action alleged that Kenvue was in violation of federal securities laws - having made fraudulent and misleading statements, including omissions, about the company's internal control and financial reporting.

[30][31] This was specifically in relation to Kenvue's Registration Statement which is said not to have disclosed information pertaining to possible risks and potential litigation regarding phenylephrine, its uses and efficacy.